Myriad Genetics, Inc.
MYGN
$7.42
$0.050.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -42.50M | -22.10M | -36.70M | -26.00M | -31.20M |
| Total Depreciation and Amortization | 14.80M | 15.60M | 15.10M | 15.70M | 15.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.50M | 14.50M | 26.50M | 12.30M | 2.70M |
| Change in Net Operating Assets | -24.20M | -7.30M | -2.30M | -20.60M | -41.30M |
| Cash from Operations | 6.60M | 700.00K | 2.60M | -18.60M | -54.70M |
| Capital Expenditure | -3.60M | -3.50M | -5.20M | -6.70M | -10.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 8.80M | -- | -- | -- |
| Other Investing Activities | -2.30M | 2.20M | -1.20M | -400.00K | -2.00M |
| Cash from Investing | -5.90M | 7.50M | -6.40M | -7.10M | -12.00M |
| Total Debt Issued | 20.00M | 20.00M | 20.00M | 60.00M | 40.00M |
| Total Debt Repaid | -19.60M | -20.10M | -20.10M | -60.10M | -40.10M |
| Issuance of Common Stock | 2.90M | 0.00 | 3.00M | -- | 123.60M |
| Repurchase of Common Stock | -1.20M | -3.00M | -500.00K | -8.70M | -1.50M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00K |
| Cash from Financing | 2.10M | -3.10M | 2.40M | -8.80M | 121.90M |
| Foreign Exchange rate Adjustments | -700.00K | 1.20M | -700.00K | -800.00K | 700.00K |
| Miscellaneous Cash Flow Adjustments | -- | 2.30M | -2.30M | -- | -- |
| Net Change in Cash | 2.10M | 8.60M | -4.40M | -35.30M | 55.90M |